A prospective study conducted in an adult intensive care unit to measure the breakdown products of citrate during kidney dialysis

Citrate metabolism in critically ill patients receiving continuous renal replacement therapy using regional citrate anticoagulation

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12619000590167

Acronym

CiMet

Enrollment

Registered

2019-04-16

Start date

2019-07-01

Completion date

2020-06-30

Last updated

2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The primary aim of the study is to quantify to plasma concentration of citrate metabolites (eg: triglycerides) when using RCA with CRRT. We expect to establish a means and standard deviations for these plasma concentrations. Our secondary aim is to track the concentration of citrate over time.

Interventions

Regional citrate anticoagulation (RCA) is currently the preferred method of anticoagulating the extracorporeal circuit used in continuous renal replacement therapy (CRRT). The citrate solution is infused into the blood before the filter and a residual amount circulates back into the patients bloodstream prior to metabolism by the liver. At present, no consensus exists as to the ultimate metabolic fate of the infused citrate. In this study, participants undergoing CRRT using RCA will have blood collected once before commencement of CRRT, then once a day for the duration of their CRRT or for five days, which ever occurs first and then once the day after cessation of their CRRT. These samples will be analysed to ascertain both the plasma concentration of citrate as well as the potential metabolic products. Participants will be monitored according to standard ICU protocols during treatment.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Clinical requirement for RCA CRRT in patients admitted to the Sunshine Coast University Hospital Intensive Care Unit.

Exclusion criteria

Age under 18 years Patients who are pregnant Patients with a haemoglobin concentration less than 80 grams per litre Patients with advanced liver disease (Childs C) Patients likely to die within 24 hours of admission the ICU Patients with known hyperlipidaemic states (eg: pancreatitis) Patients taking lipid lowering drugs (eg: statins) Known hypersensitivity or allergy to citrate compounds

Outcome results